Clinical Trial Update: Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient [NA]

View source ↗

Summary

A clinical trial update evaluating the safety profile and immunologic biomarkers of Rapamune (sirolimus) in stable renal transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Allograft Rejection

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Seoul St. Mary's Hospital | Conditions: Acute Rejection of Renal Transplant | NA | Status: UNKNOWN